

Chicago Specials

Fall Group Meeting

OCTOBER 8 - 10, 2026



Gastrointestinal Committee

Gastrointestinal Committee

Leadership

Chair: Philip A. Philip, MD, PhD
 Vice-Chair: Elena Gabriela Chiorean, MD, FASCO
 Executive Officer: Hagen F. Kennecke, MD
 Statisticians: Katherine A. Guthrie, PhD
 Sarah Colby, MS
 Sara Threlkel, BS

Scientific Leadership

Gastroesophageal: Syma Iqbal, MD
 Zev A. Wainberg, MD
 Pancreatic: Davendra P.S. Sohal, MD
 Andrew M. Lowy, MD (Surgical representative)
 Hepatobiliary: Anthony B. El-Khoueiry, MD
 Rachna T. Shroff, MD
 Syed A. Ahmad, MD (Surgical representative)
 Colon: Marwan G. Fakih, MD
 Philip J. Gold, MD
 Sepideh Gholami, MD (Surgical representative)
 Neuroendocrine Tumors: Nageshwara Arvind Dasari, MD
 Aman Chauhan, MD
 Ano-Rectal: Lisa A. Kachnic, MD
 Hagen F. Kennecke, MD
 Imaging: Anthony F. Shields, MD, PhD
 Pathology: Mary Kay Washington, MD, PhD
 Radiation Oncology: Lisa A. Kachnic, MD
 Surgery: Stephen W. Behrman, MD
 Syed A. Ahmad, MD
 Flavio Rocha, MD
 Translational Medicine: Gabriel N. Duda, PhD, DMD
 Eric Collisson, MD
 HEARD: Rachel Safyan, MD
 Colmar Figueroa-Moseley, PhD, MPH

Designates

Cancer Control Liaisons: Jason A. Zell, DO (Prevention)
 Vincent Chung, MD (Palliative Care)
 Community Liaisons: Gary L. Buchsachner, MD, PhD (Medical Oncology)
 Mohamed E. Salem, MD (Medical Oncology)
 Flavio Rocha, MD (Surgical)
 David P. Horowitz, MD (Radiation Oncology)
 AYA Committee Liason: Christopher Cann, MD
 Veterans Affairs: TBD
 Data Coordinators: Alex Rangel, BS
 Brian Zeller
 Christine Magner

Oncology Research Professionals: Adriana Gamboa Guzman, BA
 Samantha Elliott, CCRP
 Patient Advocate (Colon): Angela "Marielle" McLeod, MHA
 Patient Advocate (Pancreatic): Lisa Craine
 Pharmaceutical Science: Jane E. Rogers, PharmD
 Safae Chouraichi, PharmD
 Sr. Protocol Project Manager: Andrea Garcia, BA
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Friday, October 9, 2026 4:30 p.m. - 6:30 p.m.
 Room: Crystal C (Lobby Level)

Agenda

- Welcome
- Announcements & Introductions Philip Philip
E. Gabriela Chiorean
- HEARD Subcommittee Initiatives Rachel Safyan, Marielle McLeod, .
Colmar Figueroa-Moseley
- Featured Presentation Topic & Speaker Forthcoming
- SWOG Led Active Trials
 - S2104 Heloisa Soares/S. Ahmad
 - S2012 David Zhen/E. Gabriela Chiorean
 - S2303 Anwaar Saeed/Paul Oberstein
 - S2408 Jonathan Sham/Venu Pillarisetty
 - S2433 Rachael Safyan/E. Gabriela Chiorean
- Upcoming SWOG Trial Activations
 - S2605 Sameer Patel/Sean Dineen
- Gastroesophageal
 - Major recent clinical results Syma Iqbal, Zev Wainberg
 - NCTN trials update
 - Future SWOG plans
- Pancreatic
 - Major recent clinical results Davendra Sohal, Andrew Lowy
 - NCTN trials update
 - Future SWOG plans

Gastrointestinal Committee

9. Colon

Marwan Fakih, Philip Gold,
Sepideh Gholami

- a. Major recent clinical results
- b. NCTN trials update
- c. Future SWOG plans

10. Anal and Rectal

Hagen Kennecke, Lisa Kachnic

- a. Major recent clinical results
- b. NCTN trials update
- c. Future SWOG plans

11. Hepatobiliary

Anthony El-Khoueiry
Rachna Shroff

- a. Major recent clinical results
- b. NCTN trials update
- c. Future SWOG plans

12. Neuroendocrine

Arvind Dasari, Aman Chauhan

- a. Major recent clinical results
- b. NCTN trials update
- c. Future SWOG plans

13. Discussion/Other Business

14. Adjourn

Gastroesophageal

Active Studies

S2303, "Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMMUNE)" Study Chairs: A. Saeed and P. Oberstein. Activated: 5/6/2024.

A022102, "Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma" SWOG Champion: P. Oberstein. Activated: 1/17/2019.

EA2174, "A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma" SWOG Champion: S. Iqbal. Activated: 1/17/2019. Temporarily closed to accrual as of 12/29/2022.

EA2212, "A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer" SWOG Champion: Emerson Chen. Temporarily closed to accrual as of 12/04/2024.

Closed Studies

A021302, "Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study" SWOG Champion: S. Iqbal. Activated by SWOG: 4/1/2016. Closed to accrual on 06/01/2017.

EA2183, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2-Negative Esophageal and Gastric Adenocarcinoma (EGA)" SWOG Champion: D. Horowitz. Activated: 2/6/2020. Closed to accrual as of 05/23/2025.

Pancreatic

Active Studies

S2408, "A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula" Study Chairs: J. Sham, V. Pillarisetty, and R. Krouse. Activated: 2/14/2025. Temporarily closed to accrual as of 03/16/2026; reopening anticipated by the end of 2026.

S2433, "Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma" Study Chairs: R. Safyan, E. Chiorean, and H. Singh. Activated: 12/26/2025.

EA2192, "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation" SWOG Champions: E. Chiorean and P. Philip. Activated: 4/29/2021.

Closed Studies

S2001, "Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or 2 Mutations" Study Chairs: V. Chung and M. Pishvaian. Activated: 12/04/2020. Closed to accrual as of 10/23/2025.

S1505, "Preoperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Randomized Phase II Study" Study Chair: D. Sohal. Activated: 10/12/2015. Closed: 4/20/2018.

EA2186, "A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment-Naïve Metastatic Pancreatic Cancer (GIANT)" SWOG Champion: D. Zhen. Activated: 6/18/2020. Closed to accrual as of 10/17/2023.

Gastrointestinal Committee

RTOG-0848, "Gemcitabine, with and without Erlotinib, Followed by a Second Randomization with and without Chemoradiation, as Adjuvant Treatment for Pancreatic Head Cancer: A Phase III RTOG/SWOG/NCIC/EORTC Study" SWOG Champion: P. Philip. Activated by SWOG: 12/15/2009. Closed to accrual and treatment as of 01/18/2019.

A021501, "Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas" SWOG Champion: S. Ahmad. Activated by SWOG: 12/15/2016. Closed to accrual as of 05/06/2019.

A022106, "A Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)" SWOG Champion: G. Botta. Activated: 12/1/2023. Closed to accrual as of 12/24/2025.

A021806, "A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer" SWOG Champion: S. Behrman. Activated: 7/1/2020. Closed to accrual as of 01/05/2026.

Neuroendocrine

Active Studies

S2104, "A Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors" Study Chairs: H. Soares and S. Ahmad. Activated: 10/14/2021.

S2012, "Randomized Phase II/III Trial of First-Line Platinum/Etoposide with or without Atezolizumab in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)" Study Chairs: D. Zhen, E. Chiorean, E. Burgess, E. Swisher, and L. Byers. Activated: 12/02/2021.

CCTG-NE1, "NET RETREAT: A Phase II Study of 177Lutetium-DOTATATE Retreatment vs. Everolimus or Sunitinib or Cabozantinib in Metastatic/Unresectable Gastroenteropancreatic Neuroendocrine Tumours" Activated by SWOG: 6/17/2022.

Closed Studies

A021602, "Randomized Double-Blinded Phase III Study of Cabozantinib versus Placebo in Advanced Neuroendocrine Tumors after Progression on Prior Therapy (CABINET)" SWOG Champion: J. Strosberg. Activated: 7/18/2018. Closed to accrual as of 09/08/2023.

EA2142, "Randomized Phase II Study of Platinum and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas" SWOG Champion: H. Soares. Activated: 11/6/2015. Closed to accrual and treatment as of 04/01/2021.

EA2161, "A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)" Activated: 2/1/2017. Closed to accrual and treatment as of 12/27/2019.

A021804, "A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma" SWOG Champion: C. Lopez. Activated: 11/2/2020. Closed to accrual as of 06/02/2025.

Hepatobiliary

Closed Studies

S1815, "A Randomized Phase III Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin Alone in Advanced Biliary Cancers" Study Chairs: R. Shroff and A. Scott. Activated: 12/3/2018. Closed: 02/15/2021.

NRG-GI003, "A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma" SWOG Champion: A. El-Khoueiry. Activated: 6/21/2017. Closed to accrual as of 01/14/2026.

EA2187, "A Phase II Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma" SWOG Champion: Stacy Stein. Activated: 1/31/2020. Closed to accrual as of 03/22/2023.

RTOG-1112, "Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma" SWOG Champion: T. Mitin.

EA2197, "Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial" SWOG Champion: F. Rocha. Activated: 12/22/2020. Closed to accrual as of 04/18/2025.

Colorectal

Active Studies

A022101, "A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)" SWOG Champion: S. Gholami. Activated: 1/10/2023.

Gastrointestinal Committee

EA2222, "A Randomized Phase III Study of Systemic Therapy with or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial" SWOG Champion: Skye C. Mayo. Activated: 10/19/2023.

NRG-GI008, "Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)" SWOG GI Committee Co-Chairs: P. Philip and C. Eng. Activated: 03/10/2022.

In Development

S2605, "A Phase III Trial of Preoperative Chemotherapy vs. Surgery First (CRS-HIPEC) for High-Grade Appendiceal Cancer" Study Chairs: S. Patel, S. Dineen, and K. Raghav. In development; target activation: 12/15/2026.

Closed Studies

S1922, "Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma" Study Chair: M. Overman. Activated: 12/16/2019. Closed: 7/15/2026.

S2107, "Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab for Patients with Microsatellite Stable, BRAF V600E Metastatic Colorectal Cancer" Study Chair: V. Morris. Activated: 06/06/2022. Closed to accrual: 10/1/2024.

S1613, "A Randomized Phase II Study of Trastuzumab and Pertuzumab Compared to Cetuximab and Irinotecan in Advanced/Metastatic Colorectal Cancer with HER2 Amplification" Study Chair: K. Raghav. Activated: 10/19/2017. Step 3 permanently closed: 11/30/2023.

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High-Risk Adenomas and Second Primary Colorectal Cancers (PACES)" Study Chair: J. Zell. Activated: 3/1/2013. Permanently closed: 6/30/2023.

A021502, "Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC)" SWOG Champion: G. Lieu. Activated: 9/12/2017. Closed to accrual as of 01/17/2023.

A021703, "Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)" SWOG Champion: S. Cohen. Activated: 9/30/2019. Closed to accrual as of 12/15/2022.

E7208, "A Randomized Phase II Study of Irinotecan and Cetuximab With or Without Ramucirumab in Advanced KRAS Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy"

SWOG Champion: H. Hochster. Activated: 10/18/2010. Closed to accrual as of 7/07/2017.

NRG-GI004 / S1610, "Colorectal Cancer Metastatic MSI-High Immuno-Therapy (COMMIT): A Randomized Phase III Study of mFOLFOX6/Bevacizumab with or without Atezolizumab or Atezolizumab Monotherapy" SWOG Champion: M. Overman. Activated: 11/7/2017. Closed to accrual as of 09/02/2025.

NRG-GI005, "Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)" SWOG Champion: A. Scott. Activated: 12/16/2019. Closed to accrual as of 02/12/2024.

Rectal/Anal

Active Studies

CCTG-C032, "The NEO-RT Trial: A Phase III Randomized Trial of Neoadjuvant Chemotherapy, Excision and Observation Versus Chemoradiotherapy for Early Rectal Cancer" SWOG Champion: S. Cohen. Activated by SWOG: 7/10/2023.

Closed Studies:

N1048, "A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined-Modality Chemoradiation versus Preoperative Combined-Modality Chemoradiation for Locally Advanced Rectal Cancer" SWOG Champion: C. Eng. Activated: 4/15/2012.

EA2133 (InterAACT), "An International Multicentre Open-Label Randomised Phase II Trial Comparing Cisplatin plus 5-Fluorouracil Versus Carboplatin plus Weekly Paclitaxel in Advanced Anal Cancer" SWOG Champion: V. Morris. Activated: 2/15/2016.

NRG-GI002, "A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer" SWOG Champion: L. Kachnic. Activated: 10/12/2016. Closed to accrual as of 05/14/2019.

EA2165, "A Randomized Phase II Study of Nivolumab After Combined-Modality Therapy in High-Risk Anal Cancer" SWOG Champion: V. Morris. Activated: 4/13/2018. Closed to accrual as of 04/04/2022.

A022104, "The JANUS Rectal Cancer Trial: A Randomized Phase II Trial Testing Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Locally Advanced Rectal Cancer" SWOG Champion: A. Dasari. Activated: 11/9/2022. Closed to accrual as of 07/21/2025.

Gastrointestinal Committee

EA2176, “Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer” SWOG Champion: V. Morris. Activated: 10/15/2020. Closed to accrual as of 09/23/2024.

EA2201, “A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma” SWOG Champion: R. Hsieh. Activated: 5/13/2021. Closed to accrual as of 01/14/2025.

EA2182, “A Randomized Phase II Study of De-Intensified Chemoradiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)” SWOG Champion: J. Murphy. Activated: 11/12/2019. Closed to accrual as of 10/30/2024.

S2001 Randomized Phase II Trial of Olaparib Plus Pembrolizumab Versus Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer with Germline BRCA1/2 Mutations: SWOG S2001. Chung V, Guthrie KA, Pishvaian MJ, Lowy A, Sohal DSS, Colby S, Reiss KA, Khan G, Winograd R, Meyerhardt J, O'Reilly E, Chiorean EG, Philip PA. Submitted 2026.

Publications

The publication papers listed below from 2026 have not appeared as published in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

A021502 Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, Matin K, Cohen DJ, Potter SL, Nixon AB, Kottschade LA, Kathol E, Frankel WL, Shergill A, Hsu D, Reinacher-Schick A, Mehan P, Gold PJ, Khalil MF, Zemla T, Gatten C, O'Reilly EM, Meyerhardt JA. New England Journal of Medicine. 2026. <https://pubmed.ncbi.nlm.nih.gov/41880612/>

NRG-GI004/S1610 COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer. Lima CMSPR, Yothers G, George TJ, Hochster HS, Sanoff HK, Cohen DJ, Guthrie KA, Jacobs SA, Saeed A, Kopetz S, Colangelo LH, Freeman TJ, Cole SW, Khalil MF, Devanna S, Zuckerman DS, Hong TS, Henry NL, Ganz PA, Blanke CD, Wolmark N, Overman MJ. Journal of Clinical Oncology. 2026. <https://pubmed.ncbi.nlm.nih.gov/42525921/>

Submitted Manuscripts

C80702 Prognosis-Informed Phenotype Assignment: A Novel In-Situ Single-Cell Analysis Method for Phenotype Discovery. Lau M, Vayrynen J, Haruki K, Ma C, Vayrynen S, Ugai T, Gu S, Borowsky J, Zhao M, Arima K, Dias Costa A, Shields A, Innocenti F, KitTan W, Shi Q, Giannakis M, Fuchs C, Yu K, Nowak J, Ogino S. Submitted 2025.

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S1922	S2001	S2104	S2303	S2433	A021806	A022001	A022101	A022102
Banner MD Anderson Cancer Center	-	-	-	-	-	-	-	-	-
Baptist Mem Health Care/Mid South NCORP Consortium	-	2	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
Boston Medical Center	-	-	-	-	-	1	-	-	3
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	2	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	1	-	-	-	-	-	-	-
Cancer Research of Wisc & Northern Michigan Consort	-	-	-	3	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	1	1	4	1	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	4	5	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	6	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	3	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	2
Fred Hutchinson Cancer Research Center LAPS	-	-	3	-	-	2	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	-	-	-	-	-	-	-	1	-
Heartland Cancer Research NCORP	1	1	-	-	-	-	-	-	-
Henry Ford Hospital	-	4	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	1	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	1	-	-	4	-	1	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-
Massachusetts Vets Epidemiology Research & Information Center	-	-	-	-	-	-	-	-	-
Medical University of South Carolina NCORP Community Site	-	-	1	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	2	2	-	5	-	-	-	-	-
Moffitt Cancer Center	-	-	2	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	1	1	-	-	-	-	-
Mount Sinai Braman Comprehensive Cancer Center	-	1	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	1	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	1	-	-	-
Northwestern University LAPS	1	-	1	2	-	1	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	1	-	-	-	-	-	-
Oregon Health and Science University	-	-	4	4	-	5	-	-	-
Pacific Cancer Research Consortium NCORP	1	2	6	1	-	-	-	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	S1922	S2001	S2104	S2303	S2433	A021806	A022001	A022101	A022102
Regents of the University of Michigan	4	3	4	-	-	4	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	2	4	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	1	-	-	-	-	-	-	1
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	2	-	-	-
The Hawaii NCORP	-	-	-	2	-	-	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	-	-	-	1	-	-	-	-	8
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	2	-	-	-	-	-	-	7
UC San Diego Moores Cancer Center	-	-	-	1	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	6	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	1	3	-	-	-	-	2
U of Alabama at Birmingham/Deep South Research Consort LAPS	-	-	-	-	-	-	-	-	1
University of Arizona LAPS	-	-	11	-	-	1	-	-	-
University of Arkansas for Medical Sciences	-	-	-	2	-	-	-	-	-
University of California Davis Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	1	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	4	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	5	-	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	3	-	-	-	-	1
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	-
University of Rochester LAPS	1	-	-	3	-	12	-	-	9
University of Texas Health Science Center at San Antonio	-	-	-	-	-	3	-	-	-
University of Texas MD Anderson Cancer Center LAPS	17	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	7	2	-	-	1	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	5	-	1	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-
Wayne State University/Karmanos Cancer Institute	-	1	-	-	-	-	-	-	7
Wisconsin NCI Community Oncology Research Program	-	-	1	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	1	2	4	-	2	1	-	-
ALLIANCE	12	8	13	32	1	-	-	-	-
ECOG-ACRIN	3	16	13	12	-	-	-	-	-
NRG	3	9	10	7	-	-	-	-	-
Total	47	73	103	106	1	37	2	1	41

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	A022104	CCTGC032	CCTGNE1	EA2174	EA2192	EA2197	EA2222	EA2234	NRGG1004
Banner MD Anderson Cancer Center	-	-	-	-	-	-	1	-	-
Baptist Mem Health Care/Mid South NCORP Consortium	-	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	13	-	-	-	-	-	-	-	-
Boston Medical Center	6	-	-	2	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	2	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	2	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-	-
Cancer Research of Wisc & Northern Michigan Consort	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	9	3	-	-	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	-	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	5	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	1
Intermountain Medical Center	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-
Massachusetts Vets Epidemiology Research & Information Center	-	-	-	-	-	-	-	-	-
Medical University of South Carolina NCORP Community Site	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-
Mount Sinai Braman Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	1	-	1	-	-	-
Northwestern University LAPS	-	-	-	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	4	-	-	-	-	-	-
Oregon Health and Science University	-	3	-	-	4	6	2	-	-
Pacific Cancer Research Consortium NCORP	-	2	-	-	-	-	-	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	A022104	CCTGCO32	CCTGNE1	EA2174	EA2192	EA2197	EA2222	EA2234	NRGG1004
Regents of the University of Michigan	1	-	-	-	-	-	1	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	2	-	-	-	-
The Don and Sybil Harrington Cancer Center	1	-	-	-	-	-	-	-	-
The Hawaii NCORP	-	-	-	-	-	-	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	-	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	17	-	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	5	3	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	1	-	-	1	-	-	-	-	-
U of Alabama at Birmingham/Deep South Research Consort LAPS	-	-	-	-	-	-	-	-	-
University of Arizona LAPS	-	-	1	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-	-
University of California Davis Comprehensive Cancer Center	4	-	-	-	-	1	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	2	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	4	1	-
University of Nebraska Medical Center	-	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	-
University of Rochester LAPS	23	-	-	-	-	-	-	-	1
University of Texas Health Science Center at San Antonio	8	-	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-	13
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	9	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	8	1	-	-	-	1	-	-	-
Wayne State University/Karmanos Cancer Institute	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-
Total	110	14	7	6	6	9	8	1	15

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	NRGGI006	NRGGI008
Banner MD Anderson Cancer Center	-	-
Baptist Mem Health Care/Mid South NCORP Consortium	-	2
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	1
Boston Medical Center	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-
Cancer Research Consortium of West Michigan NCORP	-	-
Cancer Research for the Ozarks NCORP	-	-
Cancer Research of Wisc & Northern Michigan Consort	-	-
Carle Cancer Center NCI Comm Oncology Research Program	-	-
Cedars-Sinai Medical Center	-	-
City of Hope Comprehensive Cancer Center	-	-
CommonSpirit Health Research Institute	-	-
Dayton NCI Community Oncology Research Program	-	1
Essentia Health NCI Community Oncology Research Program	-	-
Fred Hutchinson Cancer Research Center LAPS	-	14
Gulf South Clinical Trials Network (Gulf South NCORP)	-	-
Heartland Cancer Research NCORP	-	-
Henry Ford Hospital	-	1
Houston Methodist Hospital	-	-
Intermountain Medical Center	-	2
Kaiser Permanente NCI Community Oncology Research Program	-	-
Loma Linda University Medical Center	-	1
Massachusetts Vets Epidemiology Research & Information Center	-	3
Medical University of South Carolina NCORP Community Site	-	-
Michigan Cancer Research Consortium NCORP	-	-
Moffitt Cancer Center	-	-
Montana Cancer Consortium NCORP	-	-
Mount Sinai Braman Comprehensive Cancer Center	-	-
Mount Sinai Hospital	-	1
NCORP of the Carolinas (Prisma Health NCORP)	-	-
Northwell Health NCORP	-	1
Northwestern University LAPS	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-
Oregon Health and Science University	-	-
Pacific Cancer Research Consortium NCORP	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	NRGGI006	NRGGI008
Regents of the University of Michigan	-	-
STCC at DHR Health Institute for Research and Development	-	1
Southeast Clinical Oncology Research Consortium NCORP	-	-
Sutter Cancer Research Consortium	-	2
The Don and Sybil Harrington Cancer Center	-	-
The Hawaii NCORP	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	-	-
The West Clinic - Wolf River	-	5
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-
UC San Diego Moores Cancer Center	-	-
UPMC Hillman Cancer Center LAPS	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-
U of Alabama at Birmingham/Deep South Research Consort LAPS	-	-
University of Arizona LAPS	-	-
University of Arkansas for Medical Sciences	-	-
University of California Davis Comprehensive Cancer Center	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-
University of Colorado Cancer Center LAPS	-	11
University of Kentucky/Markey Cancer Center	-	-
University of Nebraska Medical Center	-	-
University of Oklahoma Health Sciences Center LAPS	1	1
University of Rochester LAPS	-	19
University of Texas Health Science Center at San Antonio	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	3
Virginia Mason Medical Center	-	-
Wayne State University/Karmanos Cancer Institute	-	-
Wisconsin NCI Community Oncology Research Program	-	-
Yale University - Yale Cancer Center LAPS	-	-
ALLIANCE	-	-
ECOG-ACRIN	-	-
NRG	-	-
Total	1	69

